GlassScriptPhysician profile
Renan Amador
NPI 1487219721
$2,759.71
in general payments reported to CMS, 2019-2025
22 companies · $473 in 2025
The $473 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.27 · 2022: $152 · 2023: $853 · 2024: $1,243 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,470 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.14 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.22 | 2021-2025 | Rinvoq |
| Mallinckrodt Hospital Products INC. | $334.08 | 2024-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $274.37 | 2023-2024 | Strensiq |
| Ucb, INC. | $260.88 | 2022-2025 | Bimzelx, Cimzia |
| Amgen INC. | $246.62 | 2022-2025 | Prolia, Evenity, Tavneos |
| Aurinia Pharma U.S., INC. | $207.32 | 2023-2025 | Lupkynis |
| Genzyme Corporation | $186.57 | 2023-2024 | |
| Lilly USA, LLC | $111.58 | 2022-2023 | Taltz |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $90.73 | 2023-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $76.93 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.53 | 2024 | |
| Pfizer INC. | $63.40 | 2024 | |
| Sobi, INC | $56.99 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $52.40 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $48.01 | 2024 | |
| Ani Pharmaceuticals, INC. | $33.43 | 2024 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $27.97 | 2024 | Arcalyst |
| Janssen Biotech, INC. | $25.43 | 2022 | |
| Alvogen INC | $24.62 | 2024 | Teriparatide |
| Fresenius Kabi USA, LLC | $24.00 | 2024 | Idacio |
| Octapharma USA, INC. | $14.63 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renan Amador listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.